FORUM - ALLIANCE DE FOUNEX

"LA SANTÉ À L'ÈRE NUMÉRIQUE"

Données, intelligences artificielles et santé : espoirs et défis

Christian LOVIS

Hôpitaux Universitaires Genève
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, M.D., Jeffery R. Infante, M.D., Adil Daud, M.D., Rene Gonzalez, M.D., Richard F. Kefferd, M.D., Ph.D., Jeffrey Sosman, M.D., Omid Hamid, M.D., Lynn Schuchter, M.D., Jonathan Cebon, M.D., Ph.D., Nageatte Ibrahim, M.D., Ragini Kudchadkar, M.D., Howard A. Burris, III, M.D., Gerald Falchook, M.D., Alain Algazi, M.D., Karl Lewis, M.D., Georgina V. Long, M.D., Ph.D., Igor Puzanov, M.D., M.S.C.I., Peter Lebowitz, M.D., Ph.D., Ajay Singh, M.D., Shonda Little, M.P.H., Peng Sun, Ph.D., Alicia Allred, Ph.D., Daniele Ouellet, Ph.D., Kevin B. Kim, M.D., Kiran Patel, M.D., M.B.A., and Jeffrey Weber, M.D., Ph.D.


BACKGROUND

Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.
LAS VEGAS, Jan. 6, 2016 /PRNewswire/ -- Today at the Consumer Electronics Show, L'Oreal unveiled My UV Patch, the first-ever stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. The new technology arrives at a time when sun exposure has become a major health issue, with 90% of non-melanoma skin cancers being associated with exposure to ultraviolet (UV) radiation from sun* in addition to attributing to skin pigmentation and photoaging.

To address these growing concerns, L’Oreal Group’s leading dermatological skincare brand, La Roche-Posay, is introducing a first-of-its-kind stretchable electronic, My UV Patch. The patch is a transparent adhesive that, unlike the rigid wearables currently on the market, stretches and adheres directly to any area of skin that consumers want to monitor. Measuring approximately one square inch in area and 50 micrometers thick—half the thickness of an average strand of hair—the patch contains photosensitive dyes that factor...
Business Report

IBM Aims to Make Medical Expertise a Commodity

Big Blue thinks its Jeopardy! champion Watson can make money by offering health-care providers new expertise without hiring new staff.

by Tom Simonite    July 21, 2014
A company called Zebra Medical Vision (Zebra-Med) has unveiled a new service called Zebra AI1 that uses algorithms to examine your medical scans for a dollar each. The deep learning engine can examine CT, MRI and other scans and automatically detect lung, liver, heart and bone diseases.

New capabilities like lung and breast cancer, brain trauma, hypertension and others are "constantly being released," the company says. The results are then passed on to radiologists, saving them time in making a diagnosis or requesting further tests.
Google is using 46 billion data points to predict the medical outcomes of hospital patients
la connaissance médicale

http://dan.corlan.net/medline-trend

2'796/jour
5'623 journaux
86'468 gènes
Rigorous replication effort succeeds for just two of five cancer papers

By Jocelyn Kaiser | Jan. 18, 2017, 1:00 PM

The first results of a high-profile effort to replicate influential papers in cancer biology are roiling the biomedical community. Of the five studies the project has tackled so far, some involving experimental treatments already in clinical trials, only two could be repeated; one could not, and technical problems stymied the remaining two replication efforts.
In the early 1980s, a fifth component was added to these four "classic" bases, called methyl-cytosine (mC), which is derived from cytosine. Then, in the late 1990s, mC was recognized as the main cause of epigenetic mechanisms. Meaning, it can switch genes on or off depending on the physiological needs of each tissue.

In recent years, researchers have studied this fifth DNA base in more detail because it seems alterations in the mC base contribute to the development of many human diseases, including cancer.

Now, according to new findings published in the journal Cell, a sixth possible DNA base may also exist. Called methyl-adenine (mA), this potential DNA base may also help determine the epigenome and would therefore be key in the life of the cells.
Grippe-Trends analysieren - Schweiz


Landesweit

2014-2015 Vorjahre
When Google got flu wrong

US outbreak foxes a leading web-based method for tracking seasonal flu.

Declan Butler
13 February 2013

Google Flu Trends gets it wrong three years running

18:00 13 March 2014 by Hal Hodson
For similar stories, visit the Bird Flu Topic Guide

Google may be a master at data wrangling, but one of its products has been making bogus data-driven predictions. A study of Google's much-hyped flu tracker has consistently overestimated flu cases in the US for years. It's a failure that highlights the danger of relying on big data technologies.

https://www.youtube.com/watch?v=CxAxRCv9WoA
Messerli FH.

Chocolate consumption, cognitive function, and Nobel laureates.


PubMed PMID: 23050509h

Figure 1. Correlation between Countries’ Annual Per Capita Chocolate Consumption and the Number of Nobel Laureates per 10 Million Population.
A beauty contest was judged by AI and the robots didn't like dark skin

The first international beauty contest decided by an algorithm has sparked controversy after the results revealed one glaring factor linking the winners.

One expert says the results offer 'the perfect illustration of the problem' with machine bias. Photograph: Fabrizio Bensch/Reuters

The first international beauty contest judged by "machines" was supposed to use objective factors such as facial symmetry and wrinkles to identify the most attractive contestants. After Beauty.AI launched this year, roughly 6,000 people from more than 100 countries submitted photos in the hopes that artificial intelligence, supported by complex algorithms, would determine that their faces
Does PatientsLikeMe sell my information?

Yes, we do. We create partnerships between you, our patients, and the companies that are developing products to help you. To do that, we take the information you entrust to us and sell it to the companies that can use that data to improve or understand products or the disease market. The personally identifiable information you share upon joining the site (like your name or contact information) is considered restricted and therefore not shared with partners. The data and text you enter in and around the shared parts of the site (e.g., on your profile, in the forum, symptom or treatment reports) may be shared or sold in aggregate to partners.

We also provide a voluntary opt-in service to allow partners to directly communicate with patient members through our system.

To learn more, see how we make money or read details on what is shared and sold in our Privacy Policy.
Une application de fitness dévoile la position de bases militaires secrètes

Par Pauline Verge | Mis à jour le 29/01/2018 à 20:51 / Publié le 29/01/2018 à 17:29

Tobias Schneider @tobiaschneider

Somebody forgot to turn off their Fitbit. Markers trace known military outposts, supply and patrol routes.

pic.twitter.com/7YTzoqKgDl
19:28 - 27 janv. 2018

Tobias Schneider @tobiaschneider

My focus is on Syria, but obviously works all over. French military base Madama in Niger: pic.twitter.com/1e9SRR73xS
19:57 - 27 janv. 2018
Reducing patient re-identification risk for laboratory results within research datasets

Ravi V Atreya,¹ Joshua C Smith,¹ Allison B McCoy,² Bradley Malin,¹,³ Randolph A Miller¹,⁴,⁵

*J Am Med Inform Assoc* 2013;20:95–101. doi:10.1136/amiajnl-2012-001026

### Table 1

Uniqueness for four, five, and six consecutive results of 10 representative laboratory tests and two panels (CBC and CHEM7)

<table>
<thead>
<tr>
<th>Individual laboratory tests</th>
<th>Number of consecutive laboratory tests and proportion unique (with number of items qualifying for analysis)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td>pH</td>
<td>0.590 (N=83 941)</td>
</tr>
<tr>
<td>Gluc</td>
<td>0.996 (N=133 259)</td>
</tr>
<tr>
<td>Ca</td>
<td>0.723 (N=51 905)</td>
</tr>
<tr>
<td>LymAbs</td>
<td>0.986 (N=27 591)</td>
</tr>
<tr>
<td>PCV</td>
<td>0.195 (N=201 941)</td>
</tr>
<tr>
<td>PT-INR</td>
<td>0.343 (N=47 768)</td>
</tr>
<tr>
<td>Chol</td>
<td>1.000 (N=780)</td>
</tr>
<tr>
<td>SGPT</td>
<td>0.996 (N=12 655)</td>
</tr>
<tr>
<td>CK</td>
<td>0.963 (N=6509)</td>
</tr>
<tr>
<td>Alb</td>
<td>0.649 (N=11 520)</td>
</tr>
<tr>
<td>Panel name</td>
<td>Laboratory panels</td>
</tr>
<tr>
<td>CBC (five components)</td>
<td>0.988 (N=211 777)</td>
</tr>
<tr>
<td>CHEM7 (seven components)</td>
<td>0.989 (N=239 253)</td>
</tr>
</tbody>
</table>

Abb, albumin; Ca, calcium; CBC, complete blood count; CHEM7, blood test measuring electrolytes, glucose, and renal function; Chol, cholesterol; CK, creatine kinase; Gluc, glucose; LymAbs, absolute lymphocytes; PCV, hematocrit (packed cell volume); PT-INR, international normalized ratio for prothrombin time; SGPT, serum glutamic pyruvic transaminase.